Loading…
Scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), an autonomous institute of the Department of Science and Technology, have developed TZ-48, a fluorescence lifetime-responsive small-molecule probe that detects amyloid-beta (Abeta), the earliest and most Alzheimer's-specific biomarker of the disease.
The team paired the probe with ADxFluor, a smartphone-integrated platform that reads TZ-48's change in fluorescence intensity and quantifies the Abeta load in blood serum, turning what today needs a PET or MRI suite into a potential point-of-care test.
TZ-48 crosses the blood-brain barrier, labels Abeta plaques in transgenic Alzheimer's mouse brains, works with confocal laser scanning microscopy and fluorescence lifetime imaging microscopy, and detected Abeta in cerebrospinal fluid and serum accurately enough to separate diseased from healthy mice; the work is published in ACS Chemical Neuroscience.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by memory loss, cognitive decline and behavioural impairment. Central to its pathology is the misfolding and aggregation of the amyloid-beta peptide, which self-assembles into fibrils and is deposited outside neurons as extracellular plaques; these set off neurotoxic cascades that damage synapses and kill neurons. The second hallmark is the tau protein, which normally stabilises the internal transport skeleton of a neuron but in AD becomes abnormally modified and twists into neurofibrillary tangles inside the cell. The framework of the National Institute on Aging and the Alzheimer's Association (NIA-AA) - the US reference standard for defining AD biologically - groups the diagnostic markers into three: amyloid (A), tau (T) and neurodegeneration or neuronal injury (N), the widely cited AT(N) system, measurable in brain imaging, CSF and blood. Abeta pathology appears early and is specific to Alzheimer's, which is why a cheap Abeta test is the prize. Alzheimer's is the commonest form of dementia, but dementia is the broader umbrella - vascular dementia, Lewy body dementia and frontotemporal dementia are separate conditions.
Simple Analogy: Amyloid plaques are like sticky debris piling up between houses on a street, while tau tangles are the collapsed internal scaffolding inside each house. TZ-48 is a dye that lights up only when it touches that particular debris - and a phone camera reads how brightly it glows.
A fluorescent molecule absorbs light at one wavelength and re-emits it at a longer one. Two properties can be measured: intensity (how bright the glow is) and lifetime (how long the molecule stays in the excited state before emitting). Fluorescence lifetime imaging microscopy exploits the second, and this is the technical point of the JNCASR work: lifetime is largely independent of how much probe is present and of photobleaching (the fading of a dye under prolonged illumination), so it gives a robust, quantitative reading rather than a brightness that varies with dose. TZ-48 gives a 'turn-on' response - it is dim on its own and lights up on binding Abeta fibrils - and its distinct lifetime signatures allow differential detection across disease stages. The probe also shows blood-brain barrier (BBB) permeability. The BBB is the tight lining of the brain's capillaries, formed by endothelial cells joined by tight junctions with astrocyte and pericyte support, which blocks most large or water-soluble molecules from entering brain tissue; it protects the brain but is the single biggest obstacle in neurological drug and probe design, and a molecule that crosses it is therefore valuable well beyond this one application.
Simple Analogy: Measuring intensity is like judging a torch by how bright it looks - it depends on how close you hold it. Measuring lifetime is like timing how long the bulb takes to go dark after you switch it off: the same answer however many torches you have.
Autonomous research institute under the Department of Science and Technology; set up in 1989 to mark the birth centenary of Jawaharlal Nehru, and recognised as an Institution Deemed to be University by the UGC in 2002. Its Bioorganic Chemistry Laboratory, which produced TZ-48, works on Alzheimer's amyloids, molecular probes and biomaterials, and earlier produced the candidate anti-amyloid molecule TGR63.
Department under the Ministry of Science & Technology that funds and administers a network of autonomous science institutes (JNCASR among them) and runs the Cognitive Science Research Initiative, begun in 2008, which supports cognition and dementia research.
India's apex research funding body, created by the ANRF Act, 2023 on the recommendation of the National Education Policy 2020 and notified on 5 February 2024. It repealed and subsumed the Science and Engineering Research Board (SERB, created by an Act of 2008). Estimated outlay Rs 50,000 crore for 2023-28, of which about Rs 14,000 crore is direct budgetary support and the rest is to be raised from industry, PSUs, philanthropy and international sources. The Prime Minister is ex-officio President of its Governing Board, with the Union Ministers of Science & Technology and of Education as ex-officio Vice-Presidents; DST is the nodal department.
The NIA is one of the institutes of the US National Institutes of Health; the Alzheimer's Association is a US non-profit. Together they issued the NIA-AA Research Framework, which defines Alzheimer's biologically by biomarkers rather than symptoms and gives the AT(N) classification cited in this release.
Launched by the Ministry of Health & Family Welfare in 2010-11 to give the ageing population accessible, affordable, dedicated long-term care, following the National Policy on Older Persons and the State's obligation under the Maintenance and Welfare of Parents and Senior Citizens Act, 2007.
Key: A centrally sponsored programme delivering preventive, curative and rehabilitative geriatric care - geriatric clinics and rehabilitation services at district and sub-district hospitals, domiciliary visits for bed-ridden elderly, counselling of family caregivers - plus training of health professionals in geriatrics and research in geriatrics and gerontology.
Launched on 29 October 2024 to extend health cover to every citizen aged 70 years and above irrespective of income, BPL or APL.
Key: Free treatment cover of Rs 5 lakh a year; families already covered under AB PM-JAY get this as an additional top-up reserved for their seniors, with pre-existing conditions covered from day one.
A multi-centre government initiative to study the prevalence, incidence and risk factors of dementia in India.
Key: NIMHANS, Bengaluru is a key partner, running both community-based and hospital-based studies.
Initiated in 2008 to fund research in cognitive science, including dementia and neurodegeneration.
Key: One of the main non-ICMR routes through which Indian dementia research is supported.
Launched in 2022 by the Government of Karnataka with NIMHANS and NITI Aayog to diagnose and manage neurological conditions, including dementia, across primary, secondary and tertiary care.
Key: A state-level model for embedding brain-health screening into routine public health services.
| Aspect | PET / MRI imaging | Blood-based Abeta and tau assays | TZ-48 with ADxFluor |
|---|---|---|---|
| What it reads | Amyloid deposition and structural or metabolic change in the brain | Abeta and tau circulating in blood | Fluorescence turn-on and lifetime signature of TZ-48 on binding Abeta |
| Sample or setup | Hospital imaging suite | Laboratory assay on a blood sample | Brain tissue imaging (CLSM/FLIM), CSF or blood serum, read on a smartphone |
| Limitation cited in the release | High cost, specialised infrastructure and expertise, limited access | Expensive and complex | Demonstrated in transgenic mouse models; clinical translation is the stated next step |
| Suitability for mass screening | Low | Moderate | The stated aim - portable, low-cost, point-of-care |
Tests performed at or near the patient rather than in a central laboratory - the same design logic behind rapid antigen kits and portable glucometers. The examinable trade-off is between laboratory-grade accuracy and reach: a screening test that costs little and needs no specialist can be deployed at a primary health centre, which is exactly where India's dementia burden goes undetected.
The obstacle common to Alzheimer's, Parkinson's, brain tumours and neuro-infections. Any molecule reported to be BBB-permeable - probe or drug - is significant for that reason alone, and the phrase recurs across science-and-technology questions.
Dementia risk rises steeply with age, so India's rising share of 60+ citizens links this research to NPHCE, the Ayushman Vay Vandana Card, the Maintenance and Welfare of Parents and Senior Citizens Act 2007 and the National Policy on Older Persons.
JNCASR is one of the DST's autonomous institutes; the ANRF, created in 2023 and notified in 2024 after absorbing SERB, is the new apex channel through which such institutional research is meant to be funded, with most of its Rs 50,000 crore target expected from non-government sources.
GS Paper 3 > Science and Technology > Developments and their Applications; Indigenisation of Technology
General Awareness > Science and Technology in the News
General Awareness > Current Affairs (Science)
General Awareness > National Institutions and Schemes
Indigenous diagnostics and DST autonomous institutes appear regularly in Prelims science-and-technology and in SSC general awareness.
A peptide that misfolds and aggregates into fibrils, depositing as extracellular plaques in the Alzheimer's brain; the earliest and most Alzheimer's-specific of the core biomarkers.
A protein that normally stabilises the neuron's internal transport skeleton; in Alzheimer's it becomes abnormal and forms tangles inside the cell.
The NIA-AA classification of Alzheimer's biomarkers into amyloid (A), tau (T) and neurodegeneration (N).
How long a molecule stays excited before emitting light - a measure largely independent of probe concentration and photobleaching, and the basis of FLIM.
The selective lining of the brain's capillaries that keeps most molecules out of brain tissue; crossing it is the central challenge in neuro-diagnostics and neuro-drugs.
Testing done at or near the patient rather than in a central laboratory.